Arca
Skip to content
Tools
Tools

HCRTR1, HCRTR2: Orexin receptor

Family in Homo sapiens that 5 drugs act on.

  • Drugs that act on it: 5
  • Approved: 2
  • In phases 1 to 3: 3
  • Sponsors: 4

Who is on it, and how far along

Every drug ChEMBL records acting on HCRTR1, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 4
  • Other 1

Approved2

  • Daridorexant
  • Suvorexant

Phase 32

  • Almorexant
  • ORN-0829 hydrate

Phase 21

  • Filorexant

Phase 10

    Sponsors

    Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

    • Midnight Pharma, LLC120%
    • Taisho Pharmaceutical Co., Ltd.120%

    The landscape

    Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Orexin receptor antagonist.
    DaridorexantApprovedIdorsiaSmall moleculeAntagonist16
    SuvorexantApprovedMerck & Co. (MSD)Small moleculeAntagonist13
    AlmorexantPhase 3Midnight Pharma, LLCSmall moleculeAntagonist0
    ORN-0829 hydratePhase 3Taisho Pharmaceutical Co., Ltd.OtherAntagonist0
    FilorexantPhase 2Merck & Co. (MSD)Small moleculeAntagonist0

    Open trials

    The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 16 in all, from ClinicalTrials.gov.
    A Multicenter Observational Study of Daridorexant in the Treatment of InsomniaDaridorexant—Not yet recruitingShanghai Mental Health CenterSep 29, 2026
    A Trial to See if Daridorexant Can Help Adults and Elderly People With Insomnia Sleep Better During the Night and Function Better During the DayDaridorexantPhase 3RecruitingIdorsia Pharmaceuticals Ltd.Sep 28, 2026
    Daridorexant for Sleep Disturbance in Adults With Liver CirrhosisDaridorexantPhase 4Not yet recruitingWang FengmeiSep 21, 2026
    Study on the Management of COMISADaridorexantNot applicableRecruitingUniversity Hospital, GrenobleAug 4, 2026
    Evaluating the Efficacy and Safety of Daridorexant Transition From BZRAs in Insomnia Patients(EASY-TIP)DaridorexantPhase 4Not yet recruitingXuanwu Hospital, BeijingJul 29, 2026
    Daridorexant for People With Insomnia and Alcohol Use Disorder StudyDaridorexantPhase 2Not yet recruitingSterling McPhersonJul 14, 2026
    Suvorexant 3 - PE-PCSuvorexantPhase 4Not yet recruitingNorthern California Institute of Research and EducationJul 7, 2026
    Efficacy and Safety of Daridorexant in Patients With Major Depressive Disorder and InsomniaDaridorexantPhase 4Not yet recruitingInstitut d'Investigació Biomèdica de BellvitgeApr 29, 2026
    Daridorexant for Alcohol Use DisorderDaridorexantPhase 2Not yet recruitingJohns Hopkins UniversityApr 15, 2026
    Orexin Receptor Antagonism for the Treatment of Alcohol Use Disorder and Stress-Related DrinkingSuvorexantPhase 2RecruitingOhio State UniversityOct 9, 2025
    Orexin Antagonism for Suicide Risk: A Proof-of-Concept Clinical TrialSuvorexantPhase 2RecruitingMarianne GoodmanMar 3, 2025
    The Effects of Orexin Antagonism on Fear Extinction in PTSDSuvorexantPhase 4RecruitingVA Office of Research and DevelopmentJan 23, 2025
    Suvorexant for Treatment of AUD and PTSDSuvorexantPhase 2RecruitingPharmacotherapies for Alcohol and Substance Use Disorders AllianceNov 7, 2024
    A Study of Suvorexant (MK-4305) for the Treatment of Insomnia Disorder in Participants With Opioid Use Disorder (MK-4305-098)SuvorexantPhase 3RecruitingMerck Sharp & Dohme LLCOct 24, 2024
    Suvorexant for Alcohol Use Disorder (AUD): Neural MechanismsSuvorexantPhase 1 / Phase 2RecruitingNational Institute on Alcohol Abuse and Alcoholism (NIAAA)Jul 3, 2024
    Suvorexant and AlcoholSuvorexantEarly phase 1RecruitingWilliam StoopsMar 22, 2024

    Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3307226, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

    Esc

    Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

    Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.